AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A pharmaceutical preparation exhibiting gastrointestinal absorbability comprising a mixture of following (a) and (b):

(a) a compound recognized by a ~~proton-coupled~~peptide transporter 1, and

(b) a pH-sensitive polymer,

wherein the pH-sensitive polymer is present in an amount sufficient to impart to the gastrointestinal tract a pH at which the ~~proton-coupled~~peptide transporter 1 optimally functions for cellular uptake of the compound,

the pH-sensitive polymer being at least one member selected from the group consisting of dried methacrylic acid copolymer, methacrylic acid copolymer LD, methacrylic acid copolymer L, methacrylic acid copolymer S, polyacrylic acid, maleic acid/n-alkyl vinyl ether copolymer, hydroxpropylmethylcellulose acetate succinate, and hydroxypropylmethylcellulose phthalate, and

the amount of the pH-sensitive polymer being 5 to 40 wt % based on the weight of the entire pharmaceutical preparation.

2-4. (canceled).

5. (currently amended): The pharmaceutical preparation according to ~~Claim~~ 4Claim 1, wherein the compound recognized by the peptide transporter 1 is at least one member

selected from the group consisting of a peptide, a β-lactam antibiotic, an angiotensin-converting enzyme inhibitor, an antiviral agent, an antitumor agent, and an ω-amino carboxylic acid.

6-13. (canceled).

14. (previously presented): The pharmaceutical preparation according to Claim 1, wherein said preparation is suitable for oral administration.

15-16. (canceled).

17. (currently amended): A pharmaceutical preparation for enhancing gastrointestinal absorbability of a compound recognized by a ~~proton-coupled~~peptide transporter 1, the pharmaceutical preparation comprising a mixture of following (a) and (b):

(a) a~~the~~ compound recognized by ~~a proton-coupled~~the peptide transporter 1; and

(b) a pH-sensitive polymer in an amount sufficient for the gastrointestinal tract to acquire a pH at which the ~~proton-coupled~~peptide transporter 1 optimally transports the compound into a cell,

the pH-sensitive polymer being at least one member selected from the group consisting of dried methacrylic acid copolymer, methacrylic acid copolymer LD, methacrylic acid copolymer L, methacrylic acid copolymer S, polyacrylic acid, maleic acid/n-alkyl vinyl ether copolymer, hydroxypropylmethylcellulose acetate succinate, and hydroxypropylmethylcellulose phthalate, and

the amount of the pH-sensitive polymer being 5 to 40 wt% based on the weight of the entire pharmaceutical preparation.

18-21. (canceled).

22. (previously presented): The pharmaceutical preparation according to claim 1 or 17, wherein the amount of the pH-sensitive polymer is 10 to 20 wt% based on the weight of the entire pharmaceutical preparation.